Advertisement

Topics

Stull, Stull & Brody Launches Investigation Into Possible Breaches of Fiduciary Duty by the Board of Directors of Receptos, Inc.

20:00 EDT 21 Jul 2015 | Globe Newswire

NEW YORK, July 22, 2015 (GLOBE NEWSWIRE) -- Stull, Stull & Brody (www.ssbny.com) announces that a class action has been filed and that it is investigating potential claims on behalf of shareholders of Receptos, Inc. (NASDAQ:RCPT) ("Receptos" or the "Company") concerning whether the Company's Board of Directors breached its fiduciary duty by entering into an agreement and plan of merger under which all of the Company's outstanding shares will be acquired by Celgene Corporation for $232.00 per share in cash.

The current investigation is focused upon whether the Company's Board of Directors breached its fiduciary duty to maximize value to the Company's shareholders and to act in shareholders' best interests, including whether the Board of Directors undertook an adequate sales process and disclosed all material information to the Company's shareholders.

While the terms of the proposed transaction provide that the Company's shareholders will receive $232.00 per share in cash, at least one analyst has set a target price of $348.00 per share for the Company's stock.

Shareholders of Receptos may contact Michael J. Klein, Esq. at Stull, Stull & Brody to discuss their rights in connection with the proposed transaction by calling 1-800-337-4983, extension 147, or by email at receptos@ssbny.com.

Stull, Stull & Brody has represented shareholders in merger litigation and other securities class actions for over 40 years and has obtained court approval of substantial settlements on numerous occasions.

Attorney Advertising.  Prior Results Do Not Guarantee a Similar Outcome.

NEXT ARTICLE

More From BioPortfolio on "Stull, Stull & Brody Launches Investigation Into Possible Breaches of Fiduciary Duty by the Board of Directors of Receptos, Inc."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...